U.S. Markets close in 1 hr 46 mins

How Novartis’s Sandoz Business Has Been Performing Recently

Mike Benson
How Novartis’s Sandoz Business Has Been Performing Recently

Sandoz reported nearly flat revenue of ~$2.46 billion in the second quarter driven by a 2% favorable impact of foreign exchange and offset by a 2% fall in operating revenue in the quarter. The segment’s biopharmaceuticals portfolio reported revenue of $363 million in the second quarter, a 34% rise in operating revenue driven by an increase in US and European sales following the increased demand of the drugs Omnitrope and Zarxio in US markets and Erelzi and Rixathon in European markets.